Neumora Therapeutics Inc (NMRA) Institutional Investor Snapshot (115 Funds, Q2 2026)

NMRA ranks #4275 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

NMRA is a disclosed holding of Paul Tudor Jones (Tudor Investment Corp), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

115 institutions disclose a position in NMRA, but none treat it as a major bet — even MIC Capital Management UK LLP, its most concentrated holder, allocates just 1.9% of its own portfolio to it.

BlackRock has added to its NMRA position for two straight quarters, increasing it by $9.6M to reach $13.2M today.

Israel Englander has trimmed its NMRA position for two straight quarters, cutting it by $5.6M while still holding $865.7K.

NMRA is down 6.1% today, but institutions show net buying of $34.5M this quarter — a divergence between today's price move and the underlying institutional flow.

NMRA reported a net loss of $236.9M in its latest fiscal year.

• Not yet profitable — net loss of $236.9M in the latest fiscal year
• Net income improved year over year, from -$243.8M to -$236.9M
• Operating cash flow was negative, using $206.4M in cash
• Current ratio of 5.87x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.84x equity — within a conventional range